// App-Quantinova.ai

P-126 : Markers of tumour inflammation are prognostic for overall survival in patients with advanced pancreatic ductal adenocarcinoma receiving FOLFIRINOX chemotherapy

Researchers

Presenter

  • J. Appleyard

Principal Investigators

  • K. Kamposioras

  • G. Papaxoinis

  • F. Collinson

  • U. Ahmad

  • F. Wright

  • I. Damyanova

  • M. Razzaq

  • A. Anthoney

Medical Centers

  • Barts and the London School of Medicine, London, United Kingdom

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

  • Second department of Oncology, Agios Savvas Anticancer Hospital, Athens, Greece

  • Department of Cellular Pathology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Department of Rheumatology, Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom

  • Department of Physics, Royal Marsden NHS Foundation Trust, London, United Kingdom

Locations

  • United Kingdom

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Microphthalmia, syndromic, 9

Biomarkers

  • N/A

Drug/Treatment

  • FOLFIRINOX

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved